Tempus AI has entered into a new multi-year collaboration with Boehringer Ingelheim.

Tempus AI 与勃林格殷格翰达成了一项新的多年合作。

The partnership aims to support the development of Boehringer Ingelheim’s cancer research pipeline, building on previous work between the two companies.

该合作旨在支持勃林格殷格翰的癌症研究管线的开发，并以两家公司之前的合作为基础。

Cancer continues to pose a significant global health challenge, despite progress in treatment and diagnosis. Boehringer Ingelheim remains committed to developing new therapies for patients with difficult-to-treat cancers.

癌症仍然是全球健康面临的重大挑战，尽管在治疗和诊断方面取得了进展。勃林格殷格翰仍致力于为难治性癌症患者开发新疗法。

Through this agreement, the company will gain access to Tempus’ de-identified dataset, which includes molecular, clinical, and imaging information. Boehringer will also use Tempus’ AI-enabled platform, Lens, to support drug development efforts.

通过该协议，该公司将获取Tempus的去标识化数据集，其中包含分子、临床和影像信息。勃林格殷格翰还将使用Tempus的AI赋能平台Lens，以支持药物研发工作。

The collaboration will focus on using data from patient cohorts to identify potential biomarkers, group patients more effectively, generate ideas for drug combinations, and discover new therapeutic targets. Additionally, it will help to improve understanding of patients’ journeys through the healthcare system..

该合作将专注于利用患者群体的数据来识别潜在的生物标志物，更有效地对患者进行分组，生成药物组合的想法，并发现新的治疗靶点。此外，它还将有助于更好地理解患者在医疗系统中的历程。

By combining Tempus’ real-world patient data with Boehringer’s internal research, the two companies aim to speed up cancer drug discovery and development.

通过结合Tempus的真实世界患者数据和Boehringer的内部研究，两家公司旨在加速癌症药物的发现和开发。

The partnership reflects a shared goal of using AI and data-driven methods to deliver new treatments to patients more efficiently.

这种合作关系反映了一个共同的目标，即利用人工智能和数据驱动的方法更有效地为患者提供新的治疗方法。